Long-Term Results of a Phase-I/II Study of Sequential High-Dose Chemotherapy with Autologous Stem Cell Transplantation in the Initial Treatment of Aggressive Non-Hodgkin's Lymphoma

Coiffier B. : State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol, 23: 6387–6393, 2005.

Shipp M.A. , Harrington D.P. , Anderson J.R. , Armitage J.O. , Bonadonna G. , Brittinger G. , Cabanillas F. , Canellos G.P. , Coiffier B. , Connors J.M. , Cowan R.A. , Crowther D. , Dahlberg S. , Engelhard M. , Fisher R.I. , Gisselbrecht C. , Horning S.J. , Lepage E. , Lister T.A. , Meerwaldt J.H. , Montserrat E. , Nissen N.I. , Oken M.M. , Peterson B.A. , Tondini C. , Velasquez W.S. , Yeap B.Y. : A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med, 329: 987–994, 1993.

Pfreundschuh M. , Trumper L. , Kloess M. , Schmits R. , Feller A.C. , Rube C. , Rudolph C. , Reiser M. , Hossfeld D.K. , Eimermacher H. , Hasenclever D. , Schmitz N. , Loeffler M. : Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood, 104: 634–641, 2004.

Coiffier B. , Lepage E. , Briere J. , Herbrecht R. , Tilly H. , Bouabdallah R. , Morel P. , Van Den Neste E. , Salles G. , Gaulard P. , Reyes F. , Lederlin P. , Gisselbrecht C. : CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 346: 235–242, 2002.

Feugier P. , Van Hoof A. , Sebban C. , Solal-Celigny P. , Bouabdallah R. , Ferme C. , Christian B. , Lepage E. , Tilly H. , Morschhauser F. , Gaulard P. , Salles G. , Bosly A. , Gisselbrecht C. , Reyes F. , Coiffier B. : Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol, 23: 4117–4126, 2005.

Philip T. , Guglielmi C. , Hagenbeek A. , Somers R. , Van der Lelie H. , Bron D. , Sonneveld P. , Gisselbrecht C. , Cahn J.Y. , Harousseau J.L. : Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med, 333: 1540–1545, 1995.

Shipp M.A. , Abeloff M.D. , Antman K.H. , Carroll G. , Hagenbeek A. , Loeffler M. , Montserrat E. , Radford J.A. , Salles G. , Schmitz N. , Symann M. , Armitage J.O. , Philip T. , Coiffier B. : International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. J Clin Oncol, 17: 423–429, 1999.

McKelvey E.M. , Gottlieb J.A. , Wilson H.E. , Haut A. , Talley R.W. , Stephens R. , Lane M. , Gamble J.F. , Jones S.E. , Grozea P.N. , Gutterman J. , Coltman C. , Moon T.E. : Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer, 38: 1484–1493, 1976.

Bonadonna G. , Gianni L. , Santoro A. , Bonfante V. , Bidoli P. , Casali P. , Demicheli R. , Valagussa P. : Drugs ten years later: epirubicin. Ann Oncol, 4: 359–369, 1993.

Torti F.M. , Bristow M.M. , Lum B.L. , Carter S.K. , Howes A.E. , Aston D.A. , Brown B.W. , Hannigan J.F. , Meyers F.J. , Mitchell E.P. , Billingham M.E. : Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res, 46: 3722–3727, 1986.

Olivieri A. , Santini G. , Patti C. , Chisesi T. , De Souza C. , Rubagotti A. , Aversa S. , Billio A. , Porcellini A. , Candela M. , Centurioni R. , Congiu A.M. , Brunori M. , Nati S. , Spriano M. , Vimercati R. , Marino G. , Contu A. , Tedeschi L. , Majolino I. , Crugnola M. , Sertoli M.R. : Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG. Ann Oncol, 16: 1941–1948, 2005.

Kaiser U. , Uebelacker I. , Abel U. , Birkmann J. , Trumper L. , Schmalenberg H. , Karakas T. , Metzner B. , Hossfeld D.K. , Bischoff H.G. , Franke A. , Reiser M. , Muller P. , Mantovani L. , Grundeis M. , Rothmann F. , von Seydewitz C.U. , Mesters R.M. , Steinhauer E.U. , Krahl D. , Schumacher K. , Kneba M. , Baudis M. , Schmitz N. , Pfab R. , Koppler H. , Parwaresch R. , Pfreundschuh M. , Havemann K. : Randomized study to evaluate the use of high-dose therapy as part of primary treatment for “aggressive” lymphoma. J Clin Oncol, 20: 4413–4419, 2002.

Harris N.L. , Jaffe E.S. , Stein H. , Banks P.M. , Chan J.K. , Cleary M.L. , Delsol G. , De Wolf-Peeters C. , Falini B. , Gatter K.C. , Grogan T.M. , Isaacson P.G. , Knowles D.M. , Mason D.Y. , Muller-Hermelink H.K. , Pileri S.A. , Piris M.A. , Ralfkiaer E. , Warnke R.A. : A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 84: 1361–1392, 1994.

Kaplan E.L. , Meier P. : Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53: 457–481, 1958.

Schütt P. , Passon J. , Ebeling P. , Welt A. , Müller S. , Metz K. , Moritz T. , Seeber S. , Nowrousian M. : Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. Eur J Haematol, 78: 93–182, 2007.

Fisher R.I. , Gaynor E.R. , Dahlberg S. , Oken M.M. , Grogan T.M. , Mize E.M. , Glick J.H. , Coltman C.A. , Miller T.P. : Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med, 328: 1002–1006, 1993.

Vitolo U. , Liberati A.M. , Cabras M.G. , Federico M. , Angelucci E. , Baldini L. , Boccomini C. , Brugiatelli M. , Calvi R. , Ciccone G. , Genua A. , Deliliers G.L. , Levis A. , Parvis G. , Pavone E. , Salvi F. , Sborgia M. , Gallo E. : High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an “Intergruppo Italiano Linfomi” randomized trial. Haematologica, 90: 793–801, 2005.

Glass B. , Kloess M. , Bentz M. , Schlimok G. , Berdel W.E. , Feller A. , Trumper L. , Loeffler M. , Pfreundschuh M. , Schmitz N. : Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. Blood, 107: 3058–3064, 2006.

Haioun C. , Lepage E. , Gisselbrecht C. , Salles G. , Coiffier B. , Brice P. , Bosly A. , Morel P. , Nouvel C. , Tilly H. , Lederlin P. , Sebban C. , Briere J. , Gaulard P. , Reyes F. : Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol–a Groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol, 18: 3025–3030, 2000.

Gisselbrecht C. , Lepage E. , Molina T. , Quesnel B. , Fillet G. , Lederlin P. , Coiffier B. , Tilly H. , Gabarre J. , Guilmin F. , Hermine O. , Reyes F. : Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol, 20: 2472–2479, 2002.

Martelli M. , Gherlinzoni F. , De Renzo A. , Zinzani P.L. , De Vivo A. , Cantonetti M. , Falini B. , Storti S. , Meloni G. , Rizzo M. , Molinari A.L. , Lauria F. , Moretti L. , Lauta V.M. , Mazza P. , Guardigni L. , Pescarmona E. , Pileri S.A. , Mandelli F. , Tura S. : Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J Clin Oncol, 21: 1255–1262, 2003.

Fumoleau P. , Roche H. , Kerbrat P. , Bonneterre J. , Romestaing P. , Fargeot P. , Namer M. , Monnier A. , Montcuquet P. , Goudier M.J. , Luporsi E. : Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol, 17: 85–92, 2006.

Praga C. , Beretta G. , Vigo P.L. , Lenaz G.R. , Pollini C. , Bonadonna G. , Canetta R. , Castellani R. , Villa E. , Gallagher C.G. , von Melchner H. , Hayat M. , Ribaud P. , De Wasch G. , Mattsson W. , Heinz R. , Waldner R. , Kolaric K. , Buehner R. , Ten Bokkel-Huyninck W. , Perevodchikova N.I. , Manziuk L.A. , Senn H.J. , Mayr A.C. : Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep, 63: 827–834, 1979.

Basser R.L. , Abraham R. , To L.B. , Fox R.M. , Green M.D. : Cardiac effects of high-dose epirubicin and cyclophosphamide in women with poor prognosis breast cancer. Ann Oncol, 10: 53–58, 1999.

Gianni A.M. , Bregni M. , Siena S. , Brambilla C. , Di Nicola M. , Lombardi F. , Gandola L. , Tarella C. , Pileri A. , Ravagnani F. , Valagussa P. , Bonadonna G. : High-dose chemotherapy and autologous bone marrow transplantation compared with MA-COP-B in aggressive B-cell lymphoma. N Engl J Med, 336: 1290–1297, 1997.

Stewart D.A. , Bahlis N. , Valentine K. , Balogh A. , Savoie L. , Morris D.G. , Jones A. , Brown C. , Russell J.A. : Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. Blood, 107: 4623–4627, 2006.

Pettengell R. , Radford J.A. , Morgenstern G.R. , Scarffe J.H. , Harris M. , Woll P.J. , Deakin D.P. , Ryder D. , Wilkinson P.M. , Crowther D. : Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma. J Clin Oncol, 14: 586–592, 1996.

Kluin-Nelemans H.C. , Zagonel V. , Anastasopoulou A. , Bron D. , Roozendaal K.J. , Noordijk E.M. , Musson H. , Teodorovic I. , Maes B. , Carbone A. , Carde P. , Thomas J. : Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. J Natl Cancer Inst, 93: 22–30, 2001.

Milpied N. , Deconinck E. , Gaillard F. , Delwail V. , Foussard C. , Berthou C. , Gressin R. , Lucas V. , Colombat P. , Harousseau J.L. : Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med, 350: 1287–1295, 2004.

Bertz H. , Zeiser R. , Lange W. , Fetscher S. , Waller C.F. , Finke J. : Long-term follow-up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index. Ann Oncol, 15: 1419–1424, 2004.

Nademanee A. , Molina A. , O'Donnell M.R. , Dagis A. , Snyder D.S. , Parker P. , Stein A. , Smith E. , Planas I. , Kashyap A. , Spielberger R. , Fung H. , Wong K.K. , Somlo G. , Margolin K. , Chow W. , Sniecinski I. , Vora N. , Blume K.G. , Niland J. , Forman S.J. : Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: international index high and high-intermediate risk group. Blood, 90: 3844–3852, 1997.

Schmitz N. , Kloess M. , Reiser M. , Berdel W.E. , Metzner B. , Dorken B. , Kneba M. , Trumper L. , Loeffler M. , Pfreundschuh M. , Glass B. : Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma. Cancer, 106: 136–145, 2006.

Hiddemann W. , Kneba M. , Dreyling M. , Schmitz N. , Lengfelder E. , Schmits R. , Reiser M. , Metzner B. , Harder H. , HegewischBecker S. , Fischer T. , Kropff M. , Reis H.E. , Freund M. , Wormann B. , Fuchs R. , Planker M. , Schimke J. , Eimermacher H. , Trumper L. , Aldaoud A. , Parwaresch R. , Unterhalt M. : Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 106: 3725–3732, 2005.

Forstpointner R. , Dreyling M. , Repp R. , Hermann S. , Hanel A. , Metzner B. , Pott C. , Hartmann F. , Rothmann F. , Rohrberg R. , Bock H.P. , Wandt H. , Unterhalt M. , Hiddemann W. : The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 104: 3064–3071, 2004.

Khouri I.F. , Saliba R.M. , Hosing C. , Okoroji G.J. , Acholonu S. , Anderlini P. , Couriel D. , De Lima M. , Donato M.L. , Fayad L. , Giralt S. , Jones R. , Korbling M. , Maadani F. , Manning J.T. , Pro B. , Shpall E. , Younes A. , McLaughlin P. , Champlin R.E. : Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol, 23: 2240–2247, 2005.

Hequet O. , Le Q.H. , Moullet I. , Pauli E. , Salles G. , Espinouse D. , Dumontet C. , Thieblemont C. , Arnaud P. , Antal D. , Bouafia F. , Coiffier B. : Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol, 22: 1864–1871, 2004.

Armitage J.O. , Fyfe M.A. , Lewis J. : Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen. J Clin Oncol, 2: 898–902, 1984.